ER-POSITIVE HER2-NEGATIVE BREAST CANCER

This phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…

This early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…

This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…

This study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compa…